In August 2025, the government of Burkina Faso, led by military ruler Captain Ibrahim Traoré, halted all activities of the Target Malaria project—an initiative funded primarily by the Bill & Melinda Gates Foundation (in collaboration with Open Philanthropy)—that sought to curb malaria by releasing genetically modified mosquitoes.
Background & Scale of the Project
Initiated in 2012, Target Malaria focused on deploying gene-drive and sterile male mosquito technologies to disrupt malaria transmission. Burkina Faso became the first African nation to conduct such releases—starting in 2019—with further trials continuing into August 2025. The goal: suppress mosquito populations by interfering with their reproductive capacity.
Reasons for Suspension
A coalition of civil society groups, notably the Coalition for Monitoring Biotechnological Activities in Burkina Faso (CVAB), vehemently criticized the project as “highly controversial, unpredictable, and posing ethical challenges.” Concerns included:
- Lack of sufficient public consultation and community consent—especially near villages like Souroukoudingan.
- Fears of ecological risks, possible irreversible impacts on biodiversity and ecosystems.
- Allegations of scientific neo-colonialism, arguing that foreign-funded projects were using African nations as testing grounds.
Government Response & Actions Taken
On August 22, 2025, the Ministry of Higher Education, Research and Innovation announced the suspension of Target Malaria’s operations. It ordered facilities containing genetically modified mosquitoes to be sealed, and instructed that all remaining samples be destroyed under a strict protocol.
This move aligns with a broader campaign by Traoré’s military administration to limit foreign influence: earlier in 2025, the government had already revoked operating licenses of 21 international NGOs.
Implications & Future Direction
The suspension underscores a pivotal shift in public health governance—emphasizing national sovereignty and ethical oversight over potentially transformative but experimental global health initiatives. Burkina Faso reaffirmed its commitment to combating malaria through safer, more transparent methods, such as vaccine campaigns and preventive programs.
In short, Burkina Faso’s decision marks a significant milestone: a clearly articulated demand for local control, accountability, and public trust in medical and scientific interventions. It sends a powerful message that breakthrough technology must be balanced with ethical safeguards and community engagement.